Literature DB >> 11059472

Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique.

M Man-Son-Hing1, A Laupacis, A M O'Connor, D Coyle, R Berquist, F McAlister.   

Abstract

BACKGROUND: Decision analysis (DA) and the probability-tradeoff technique (PTOT) are patient preference-based methods of determining optimal therapy for individuals. Using aspirin therapy for the primary prevention of stroke and myocardial infarction (MI) in elderly persons as an example, the objective of this study was to determine whether group-level treatment thresholds and individual-level treatment recommendations derived using PTOT are identical to those of DA incorporating the patients' own values.
METHODS: Persons in a pilot study of the efficacy of aspirin in the prevention of stroke and MI were asked to participate. Participant values and utilities for pertinent health states (e.g., minor and major stroke, MI, major bleeding episode) were determined. Then, in three hypothetical clinical situations in which the chance of stroke or MI was varied, PTOT was used to directly determine treatment thresholds for aspirin therapy (i.e., the smallest reduction in MI or stroke risk for which participants would be willing to take aspirin). Using DA modeling, with the same probabilities of events as in the PTOT exercise and incorporating participants' own values, treatment thresholds for the three clinical situations were determined. The thresholds determined by the two approaches were compared. Finally, based on these treatment thresholds, using the best estimates of the efficacy of aspirin to prevent first-time stroke and MI, PTOT and DA treatment recommendations for individual participants were compared.
RESULTS: The 42 participants reported that a major stroke was the least desirable health state, followed by MI, minor stroke, and major bleeding. The minimum risk reduction required to take aspirin was greater for MI prevention compared with stroke prevention. For the two clinical situations in which the hypothetical efficacy of aspirin to prevent stroke was varied, treatment thresholds for the PTOT versus DA approaches differed (p < 0.04), but this difference was not significant (p = 0.19) for the MI-based clinical situation. Using the best estimate of the efficacy of aspirin to prevent first-time stroke and MI, PTOT and DA treatment recommendations whether or not to take aspirin were discordant for 38% of participants (16 of 42) (p < 0.001).
CONCLUSIONS: Patient preference-based group-level treatment thresholds and individual-level treatment recommendations can differ significantly depending on whether PTOT or DA is used, apparently because the two emphasize different aspects of the decision-making process. DA theory assumes that effective therapeutic decision making should maximize both quality and quantity of life; with PTOT, the emphasis for effective clinical decision making allows patients to be fully engaged in the process, thus hopefully leading to fully informed decisions that may result in satisfaction and compliance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059472     DOI: 10.1177/0272989X0002000403

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  13 in total

Review 1.  Measuring patients' preferences for treatment and perceptions of risk.

Authors:  A Bowling; S Ebrahim
Journal:  Qual Health Care       Date:  2001-09

2.  A meta-analysis of quality-of-life estimates for stroke.

Authors:  Tammy O Tengs; Ting H Lin
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 3.  Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Samantha MacLean; Sohail Mulla; Elie A Akl; Milosz Jankowski; Per Olav Vandvik; Shanil Ebrahim; Shelley McLeod; Neera Bhatnagar; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Authors:  P J Devereaux; D R Anderson; M J Gardner; W Putnam; G J Flowerdew; B F Brownell; S Nagpal; J L Cox
Journal:  BMJ       Date:  2001-11-24

5.  Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.

Authors:  Eduard Shantsila; Andreas Wolff; Gregory Y H Lip; Deirdre A Lane
Journal:  Br J Gen Pract       Date:  2015-01       Impact factor: 5.386

6.  Determining Patient Preferences for Indeterminate Thyroid Nodules: Observation, Surgery or Molecular Tests.

Authors:  Daniel Joonil Lee; Jason J Xu; Dale H Brown; Ralph W Gilbert; Patrick J Gullane; Jonathan C Irish; Lorne E Rotstein; David P Goldstein; John R de Almeida
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

7.  Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.

Authors:  Pablo Alonso-Coello; Victor M Montori; M Gloria Díaz; Philip J Devereaux; Gemma Mas; Ana I Diez; Ivan Solà; Mercè Roura; Juan C Souto; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ignasi Gich; Holger J Schünemann; Gordon Guyatt
Journal:  Health Expect       Date:  2014-05-12       Impact factor: 3.377

8.  Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudes.

Authors:  David K Lewis; Jude Robinson; Ewan Wilkinson
Journal:  BMJ       Date:  2003-10-11

Review 9.  Serum ferritin as an indicator of iron status: what do we need to know?

Authors:  Jahnavi Daru; Katherine Colman; Simon J Stanworth; Barbara De La Salle; Erica M Wood; Sant-Rayn Pasricha
Journal:  Am J Clin Nutr       Date:  2017-10-25       Impact factor: 7.045

10.  Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer.

Authors:  Milo A Puhan; Tsung Yu; Inge Stegeman; Ravi Varadhan; Sonal Singh; Cynthia M Boyd
Journal:  BMC Med       Date:  2015-10-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.